Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma is a PHASE1 clinical asset sponsored by Zhejiang University in Advanced Hepatocellular Carcinoma. SEO and diligence focus: anti-GPC3 CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Advanced Hepatocellular Carcinoma
Modality: cell therapy
Target: anti-GPC3 CAR-T
Sponsor: Zhejiang University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: anti-GPC3 CAR-T
View original source fields
Condition raw: Advanced Hepatocellular Carcinoma
Condition normalized: Advanced Hepatocellular Carcinoma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: anti-GPC3 CAR-T
Target normalized: anti-GPC3 CAR-T